āagmanLoginNot investment advice. Data and computed figures, for information only.
Concord Biotech Ltd
₹1,353.30
−₹28.80 (−2.08%)
NSE · 15 Oct 2026, close
Market Cap
₹14,242 Cr
CMP
₹1,353.30
52-wk High / Low
₹1,615 / 987
P/E
51.3
P/B
7.1
Book Value
₹193.0
Div Yield
0.55%
ROCE
17.0%
ROE
12.5%
Face Value
₹1
D/E
0.00
Price−15.6% over 1Y
āagman read
Computed by āagmanPiotroski F-Score
5
/ 9
5 of 9 F-score tests passed
Graham Number
₹329
√(22.5 × EPS × book value per share)
ROIC
10.9%
vs 11.2% sector median
Cash flow to profit
1.03
CFO / PAT
Above 1.0 = operating cash flow exceeded reported profit
Margin change
+200
bps OPM YoY
Operating margin vs the same quarter last year
Sustainable growth
9.0%
ROE × earnings retention ratio
ROE stability
2.9
pp σ
Standard deviation of ROE across periods. Lower = more stable
Holder deltas
QoQ
pp
Prom +0.00FII −0.26DII +0.15
Latest quarter vs the previous one
Cash-accrual divergence
−0.4%
of assets
Low = accruals track cash flow
Strengths
+Price trades above its 200-day moving average (1.1x)
Watch-outs
Peer comparison
| Name | P/E | Mar Cap ₹ Cr | ROCE % | ROE % |
|---|
Quarterly results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 257 |
| Expenses | 123 | 147 | 135 | 187 | 135 | 176 | 146 | 241 | 143 | 159 | 179 | 208 | 175 |
| Operating Profit | 72 | 116 | 106 | 132 | 81 | 134 | 98 | 189 | 61 | 88 | 98 | 118 | 82 |
| OPM % | 36.9% | 44.3% | 44.0% | 41.4% | 37.5% | 43.2% | 40.2% | 44.0% | 29.9% | 35.6% | 35.3% | 36.2% | 31.9% |
| Other Income | 13 | 8 | 11 | 11 | 12 | 10 | 17 | 9 | 15 | 16 | 7 | 15 | 14 |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 20 | 18 |
| Profit before tax | 71 | 110 | 103 | 129 | 80 | 130 | 101 | 184 | 59 | 86 | 86 | 114 | 78 |
| Net Profit | 54 | 81 | 78 | 95 | 60 | 96 | 76 | 140 | 44 | 63 | 64 | 88 | 58 |
| EPS (₹) | 5.21 | 7.74 | 7.41 | 9.08 | 5.70 | 9.15 | 7.26 | 13.42 | 4.21 | 6.08 | 6.16 | 8.49 | 5.59 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 512 | 616 | 713 | 853 | 1,017 | 1,200 | 1,055 | 1,108 |
| Expenses | 308 | 289 | 443 | 509 | 585 | 694 | 687 | 721 |
| Operating Profit | 205 | 327 | 270 | 344 | 432 | 506 | 368 | 388 |
| OPM % | 40.0% | 53.1% | 37.9% | 40.3% | 42.5% | 42.2% | 34.9% | 35.0% |
| Other Income | 32 | 14 | 23 | 37 | 37 | 44 | 52 | 52 |
| Interest | 1 | 1 | 6 | 5 | 3 | 1 | 1 | 0 |
| Depreciation | 21 | 28 | 50 | 54 | 54 | 54 | 74 | 75 |
| Profit before tax | 214 | 313 | 238 | 322 | 413 | 495 | 345 | 364 |
| Net Profit | 169 | 235 | 175 | 240 | 308 | 372 | 259 | 273 |
| EPS (₹) | 177.81 | 247.44 | 183.93 | 22.95 | 29.45 | 35.52 | 24.94 | 26.32 |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | — |
| Reserves | 761 | 990 | 1,094 | 1,280 | 1,516 | 1,802 | 2,007 | — |
| Borrowings | 52 | 86 | 62 | 32 | 10 | 3 | 2 | — |
| Other Liabilities | 118 | 97 | 147 | 192 | 164 | 219 | 212 | — |
| Total Liabilities | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,232 | — |
| Fixed Assets | 240 | 546 | 573 | 593 | 575 | 795 | 789 | — |
| CWIP | 141 | 18 | 74 | 173 | 211 | 51 | 79 | — |
| Investments | 199 | 141 | 74 | 137 | 246 | 335 | 491 | — |
| Other Assets | 361 | 477 | 592 | 611 | 668 | 854 | 873 | — |
| Total Assets | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,232 | — |
Cash Flows
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 155 | 167 | 207 | 246 | 265 | 245 | 267 |
| Cash from Investing Activity | −114 | −195 | −112 | −158 | −155 | −160 | −143 |
| Cash from Financing Activity | −43 | 31 | −100 | −85 | −99 | −99 | −113 |
| Net Cash Flow | −1 | 3 | −4 | 3 | 12 | −14 | 11 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 32.0 | 21.0 | 26.0 | 28.0 | 28.0 | 17.0 |
| ROE % | — | — | — | — | — | — | 12.5 |
| EPS (₹) | 177.81 | 247.44 | 183.93 | 22.95 | 29.45 | 35.52 | 24.94 |
| Book Value (₹) | — | — | — | — | — | — | 193.0 |
| Face Value (₹) | — | — | — | — | — | — | 1 |
| P/E | — | — | — | — | — | — | 51.3 |
| Div Yield % | — | — | — | — | — | — | 0.55 |
| NPM % | 31.1 | 37.3 | 23.8 | 27.0 | 29.2 | 29.9 | 23.4 |
| OPM % | 40.0 | 53.0 | 38.0 | 40.0 | 42.0 | 42.0 | 35.0 |
| D/E | 0.07 | 0.09 | 0.06 | 0.02 | 0.01 | 0.00 | 0.00 |
| P/B | — | — | — | — | — | — | 7.1 |
Growth
Compounded sales growth
5 years+11.0%
3 years+7.0%
TTM−7.0%
Compounded profit growth
5 years+1.0%
3 years+0.0%
TTM−22.0%
Stock price CAGR
3 years+6.0%
Last year−15.0%
Return on equity
5 years18.0%
3 years18.0%
Last year12.0%
Documents
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Closure of Trading WindowAnnouncement under Regulation 30 (LODR)-Newspaper PublicationShareholder Meeting / Postal Ballot-Notice of Postal BallotBoard Meeting Outcome for The Board Of Director At Its Meeting Held Today I.E. Wednesday, September 23, 2026, Has Inter-Alia Considered And Approved Issuance Of Bonus Shares & Increase In The Authorised Share Capital Of The Company.Corporate actions
24 Jul 2026DIVIDENDDividend - Rs 7.55 Per Share—
3 Sep 2025DIVIDENDDividend - Rs 10.70 Per Share—
21 Jun 2024DIVIDENDDividend - Rs 8.75 Per Share—
Fundamentals from a third-party compiler of exchange filings; prices from the exchanges. Not investment advice.© 2026 āagman